InModeNASDAQ: INMD

InMode's products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share price decline over 80% from its peak, InMode has remained profitable while continuing to innovate. The strong new and second-hand sales market for their platforms suggest their customers continue to see value in their products.

InMode Ltd. (NASDAQ:INMD ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Eran Krieger - Medical Director and VP of Medical Affairs Rafael Lickerman - Vice President, Finance Conference Call Participants Matt Miksic - Barclays Caitlin Cronin - Canaccord Genuity Sam Eiber - BTIG Operator Good day, and welcome to the InMode's Third Quarter 2024 Earnings Results Conference Call.

YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024.

IRVINE, Calif. , Oct. 24, 2024 /PRNewswire/ -- InMode Ltd.

InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd.

YOKNEAM, Israel , Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of North America effective September 30, 2024.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook.